Nifty Pharma: relative strength and momentum
Sector. Compared with Nifty 500 TRI.
As of 2026-10-23, Nifty Pharma has an ArthaNiti relative-strength score of 84 out of 100 (strong) against Nifty 500 TRI, in the Lead fading phase (still gaining, but the lead is shrinking); the score moved -2 points in four weeks. Returns use Official TRI (net of TER).
1 week−1.8%
1 month−6.3%
3 months−2.6%
6 months+9.1%
1 year+13.7%
3 years, a year+19.7%
5 years, a year+13.2%
Volatility, 1 year13.7%
Worst fall, 1 year−7.5%
Above 200-day averageYes
What is inside Nifty Pharma: holdings and weights
Nifty Pharma holds 20 stocks; the top 10 make up 78% of the index. 55% of its stocks trade above their 200-day average.
- 11 of 20 stocks (55%) are above their 200-day average — healthy participation.
- Short-term breadth (15% above 50-day) is fading faster than long-term — momentum is cooling.
- Top 10 stocks are 78% of the index; half the weight sits in 5 stocks.
- Biggest 1-month driver: Dr. Reddy's Laboratories Ltd. (+1.5%).
| Stock | Industry | Weight | 3 months | Momentum score |
|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Ltd. | Healthcare | 19.51% | −10.5% | 61 |
| DIVISLAB Divi's Laboratories Ltd. | Healthcare | 11.98% | +22.5% | 92 |
| LAURUSLABS Laurus Labs Ltd. | Healthcare | 7.82% | +25.6% | 98 |
| CIPLA Cipla Ltd. | Healthcare | 7.68% | −4.0% | 58 |
| DRREDDY Dr. Reddy's Laboratories Ltd. | Healthcare | 7.63% | +5.4% | 67 |
| TORNTPHARM Torrent Pharmaceuticals Ltd. | Healthcare | 7.17% | −10.7% | 70 |
| LUPIN Lupin Ltd. | Healthcare | 5.00% | −19.5% | 37 |
| AUROPHARMA Aurobindo Pharma Ltd. | Healthcare | 4.69% | +3.2% | 79 |
| GLENMARK Glenmark Pharmaceuticals Ltd. | Healthcare | 3.57% | −1.8% | 66 |
| ALKEM Alkem Laboratories Ltd. | Healthcare | 3.16% | −11.7% | 42 |
ETFs that track Nifty Pharma
| ETF | NSE symbol | Expense ratio | Tracking diff, 1 yr | AUM |
|---|---|---|---|---|
| Nippon India Nifty Pharma ETF | PHARMABEES | 0.23% | -0.30% | ₹1,736 Cr |
ArthaNiti publishes market data and analytics for education. It is not investment advice or a research recommendation, and ArthaNiti is not registered with SEBI as an Investment Adviser or Research Analyst.